Follicular Lymphoma International Prognostic Index
- PMID: 16916487
- DOI: 10.1007/s11864-006-0036-3
Follicular Lymphoma International Prognostic Index
Abstract
Although numerous treatment approaches are proposed for patients with follicular lymphoma, criteria to help in choosing a treatment for a given patient and for comparing trial results are lacking. Several retrospective studies have analyzed prognostic factors, but their conclusions rely on limited numbers of patients treated during long periods, and their results are discordant. The Follicular Lymphoma International Prognostic Index was designed from the data recorded over 8 years of nearly 5000 patients registered worldwide. Five factors are used (age, Ann Arbor stage, number of nodal sites, serum lactate dehydrogenase level, and hemoglobin level) to build a three-category index. This index, together with new biologic markers such as gene profiling and proteomics, could help provide an optimal treatment option for patients with follicular lymphoma.
Similar articles
-
Prognosis of follicular lymphomas.Clin Lymphoma. 2005 Jun;6(1):21-5. doi: 10.3816/clm.2005.n.022. Clin Lymphoma. 2005. PMID: 15989702 Review.
-
Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression.Ann Oncol. 2004 Oct;15(10):1484-9. doi: 10.1093/annonc/mdh406. Ann Oncol. 2004. PMID: 15367408
-
Follicular lymphoma international prognostic index.Blood. 2004 Sep 1;104(5):1258-65. doi: 10.1182/blood-2003-12-4434. Epub 2004 May 4. Blood. 2004. PMID: 15126323
-
Stage III follicular lymphoma: long-term follow-up and patterns of failure.Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):748-54. doi: 10.1016/s0360-3016(03)00641-2. Int J Radiat Oncol Biol Phys. 2003. PMID: 14529780
-
Clinical significance of serum-soluble interleukin-2 receptor in patients with follicular lymphoma.Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):410-6. doi: 10.1016/j.clml.2013.03.014. Epub 2013 Jun 5. Clin Lymphoma Myeloma Leuk. 2013. PMID: 23747081 Review.
Cited by
-
Follicular Lymphoma: Saudi Lymphoma Group's Clinical Practice Guidelines for Diagnosis, Management and Follow-up.Saudi J Med Med Sci. 2019 Sep-Dec;7(3):214-218. doi: 10.4103/sjmms.sjmms_101_19. Epub 2019 Aug 28. Saudi J Med Med Sci. 2019. PMID: 31543747 Free PMC article. No abstract available.
-
Imaging of Early Response to Predict Prognosis in the First-Line Management of Follicular Non-Hodgkin Lymphoma with Iodine-131-Rituximab Radioimmunotherapy.Diagnostics (Basel). 2017 May 12;7(2):26. doi: 10.3390/diagnostics7020026. Diagnostics (Basel). 2017. PMID: 28498337 Free PMC article.
-
Clinical characteristics, treatment patterns and outcomes of patients with follicular lymphoma in Colombia: a real-world evidence cohort study.Ann Hematol. 2025 Apr;104(4):2327-2336. doi: 10.1007/s00277-025-06341-x. Epub 2025 Apr 14. Ann Hematol. 2025. PMID: 40227475 Free PMC article.
-
The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials.Cancer Med. 2019 Jan;8(1):165-173. doi: 10.1002/cam4.1918. Epub 2018 Dec 21. Cancer Med. 2019. PMID: 30575311 Free PMC article. Clinical Trial.
-
Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma - MCT1 as potential target in diffuse large B cell lymphoma.Cell Oncol (Dordr). 2019 Jun;42(3):303-318. doi: 10.1007/s13402-019-00426-2. Epub 2019 Feb 21. Cell Oncol (Dordr). 2019. PMID: 30790227
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources